Search Results for “EC” – Page 633 – media

GSK tests mepolizumab for nasal polyps

GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
- Source: Pharmtimes
- 773
- June 28, 2017
Clinical Trials EU mepolizumab
GSK tests mepolizumab for nasal polyps

GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
- Source: pharmatimes
- 745
- June 28, 2017
asthma Company Insight EU surgery
EU regulators reviewing Shire’s bleeding disorder drug

European regulators have validated the marketing authorisation application for Shire’s experimental von Willebrand Disease therapy Veyvondi.
- Source: pharmatimes
- 600
- June 26, 2017
EU FDA genetic therapy
Drugdu.com (Ddu) attended CPhI China 2017 for new pharmaceutical industry pattern

CPhI China 2017 was held at the Shanghai New International Expo Center from June 20 to 22. As the leading global pharmaceuticals and medical devices industry platform, Ddu presented a wide range of services which connect the traditional medical industry with the Internet including one-stop service solutions, buying offer sharing of global exhibitions, credit verification and so forth.
- Source: Ddu
- 896
- June 24, 2017
App buying offers CPhI Exhibitions & Activities
Global Hemodialysis Consumables Market Analysis

As the most potential market in china, Hemodialysis market appears a large revenue space. With the opening of private hemodialysis services, private economy in the hemodialysis industry is about to take a ”Golden era”.
- Source: Ddu
- 588
- June 24, 2017
hemodialysis consumables Market Reports
US nod for CSL Behring’s HAE prevention therapy

US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary (HAE) attacks in adolescent and adults.
- Source: pharmatimes
- 428
- June 23, 2017
HAE inhibitor New Approvals
EU regulators review Novartis’ migraine drug

An experimental therapy being developed by Amgen and Novartis to prevent migraine has been accepted for review in the European Union.
- Source: pharmatimes
- 991
- June 22, 2017
antibody Clinical Trials erenumab EU New Approvals WHO
Ddu’s Golden Age in Cross-border Medical Trade

Under the background of the Internet plus era, Ddu is set up by a a talented team, consisting of experienced insiders and Internet elites. Ddu (Drugdu.com) is a global leading pharmaceuticals and medical devices B2B online platform. Different from comprehensive B2B platforms, Ddu is a vertical one focusing on the medical trade industry. It is a bold attempt for traditional industry to accelerate the transformation and upgrading.
- Source: Ddu
- 699
- June 22, 2017
cross-border medical device pharmaceutical
Drugdu.com (“Ddu”) will attend INTERPHEX JAPAN

INTERPHEX JAPAN will be held in Big Sight, Tokyo from June 28th - 30th. As the leading global pharmaceuticals and medical devices B2B online platform, Ddu will attend the fair with products from high priority members.
- Source: Ddu
- 556
- June 21, 2017
Exhibitions & Activities INTERPHEX JAPAN
A choice for Chang’an Pharmaceutical to win global orders

It is delighted that Chang'an Pharmaceutical became the 100th VIP member of Ddu. It is Ddu’s honor to invite Chang'an Pharmaceutical for the interview. Drugdu will continue to focus on the optimization of the online and offline services, committing to create more friendly, more humane medical trade ecosystem in the future.No matter it is the 1st member or the 1,000th one, Ddu will try the best. We are always with you.
- Source: drugdu
- 910
- June 20, 2017
Ddu News pharmaceutical

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.